Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 3

1(16.7%)

6Total

N/A(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05485831Recruiting

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

Role: collaborator

NCT05394779Not ApplicableCompleted

DEMETRA - ADVICE-002-2022

Role: lead

NCT05286632Not ApplicableCompleted

KidneYou - Innovative Digital Therapy

Role: lead

NCT05260203Not ApplicableCompleted

MargheRITA (Remote Intelligence for Therapeutic Adherence)

Role: lead

NCT06299553Recruiting

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Role: collaborator

NCT05622162Phase 3Active Not Recruiting

Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7

Role: collaborator

NCT05164640Not ApplicableCompleted

Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"

Role: collaborator

NCT05533099Active Not Recruiting

REGENERA Implant in Localized Non-malignant Breast Lesions Treated by Excision or Lumpectomy - Long-term Follow-up

Role: collaborator

NCT05984420Not ApplicableRecruiting

Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis

Role: collaborator

All 9 trials loaded